.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Harvard Business School
UBS
Citi
Mallinckrodt
Colorcon
AstraZeneca
Chubb
Farmers Insurance
Dow

Generated: July 23, 2017

DrugPatentWatch Database Preview

Claims for Patent: 9,278,901

« Back to Dashboard

Claims for Patent: 9,278,901

Title:Compounds and methods for delivery of prostacyclin analogs
Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
Inventor(s): Phares; Ken (Chapel Hill, NC), Mottola; David (Cary, NC), Jeffs; Roger (Chapel Hill, NC)
Assignee: United Therapeutics Corporation (Silver Spring, MD)
Application Number:14/710,694
Patent Claims: 1. A method of treating pulmonary hypertension comprising administering to a subject in needed thereof an oral pharmaceutical formulation comprising a pharmaceutically acceptable salt or ester of treprostinil which has an absolute bioavailability of at least 15%, wherein a Cmax in a plasma of the subject increases in a linear fashion with a dose of at least 0.05 mg administered to the subject and wherein a concentration of treprostinil in the plasma of the subject is at least 50 pg/ml for at least 8 hours.

2. The method of claim 1, wherein the absolute bioavailability of said salt or ester ranges from 21 to 25%.

3. The method of claim 1, wherein the oral bioavailability of the salt or ester is at least 50% greater than the oral bioavailability of treprostinil as free acid.

4. The method of claim 1, wherein the oral bioavailability of the salt or ester is at least 100% greater than the oral bioavailability of treprostinil as free acid.

5. The method of claim 1, wherein the pharmaceutically acceptable salt or ester is the diethanolamine salt of treprostinil.

6. The method of claim 1, wherein the subject is a human.

7. A method of treating pulmonary hypertension comprising administering to a subject in needed thereof an oral pharmaceutical formulation comprising a pharmaceutically acceptable salt or ester of treprostinil which has an absolute bioavailability of at least 15%, wherein an AUCinf in a plasma of the subject increases in a linear fashion with a dose of at least 0.05 mg administered to the subject and wherein a concentration of treprostinil in the plasma of the subject is at least 50 pg/ml for at least 8 hours.

8. The method of claim 7, wherein the absolute bioavailability of said salt or ester ranges from 21 to 25%.

9. The method of claim 7, wherein the oral bioavailability of the salt or ester is at least 50% greater than the oral bioavailability of treprostinil as free acid.

10. The method of claim 7, wherein the oral bioavailability of the salt or ester is at least 100% greater than the oral bioavailability of treprostinil as free acid.

11. The method of claim 7, wherein the pharmaceutically acceptable salt or ester is the diethanolamine salt of treprostinil.

12. The method of claim 7, wherein the subject is a human.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Novartis
Colorcon
Healthtrust
Baxter
Teva
Merck
Cantor Fitzgerald
Farmers Insurance
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot